Drug intelligence / Profile preview

BR1019C

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1019C is an experimental drug candidate developed by Boryung Pharmaceutical as part of a combination therapy regimen for the treatment of essential hypertension and type 2 diabetes mellitus. It is being evaluated in phase 3 clinical trials in South Korea, typically in combination with other investigational agents such as BR1019A and BR1019B. The precise mechanism of action for BR1019C has not been disclosed or defined publicly, and its molecular target remains unknown. The drug is not classified as an orphan drug and represents a new molecular entity within its development program.

Beyond the preview

Go deeper on BR1019C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1019C.

Explore the full profile